The company says that after deducting nonrecurring gains or losses, the net profit attributable to the owners of the parent for the FY2024 will range from about RMB710 million to RMB840 million. This is a decrease of approximately RMB242 million to RMB112 million compared to FY2023, reflecting a year-on-year decrease of approximately 25% to 12%.
Tianjin Pharmaceutical Da Ren Tang Group expects its net profit attributable to the owners of the parent for the FY2024 ended Dec 31, 2024 to range from around RMB2.15 billion ($400.0 million) to RMB2.39 billion.
This is an increase of around 118% to 142% y-o-y, or RMB1.16 billion to RMB1.40 billion, compared to the FY2023.
